[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100630608":3},{"organization":4,"armGroups":7,"interventions":24,"overallOfficials":30,"centralContacts":35,"locations":41,"responsibleParty":70,"collaborators":30,"id":72,"slug":73,"hasResults":74,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":78,"eligibilityCriteria":79,"healthyVolunteers":74,"sex":80,"minAge":81,"maxAge":82,"enrollmentInfo":83,"targetDuration":30,"studyType":86,"phases":87,"briefSummary":89,"conditions":90,"keywords":92,"overallStatus":44,"whyStopped":30,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":103},{"fullName":5,"class":6},"InventisBio Co., Ltd","INDUSTRY",[8,14,18],{"label":9,"type":10,"description":11,"interventionNames":12},"D-2570 low dose","ACTIVE_COMPARATOR","Low dose of D-2570",[13],"Drug: D-2570 Tablet",{"label":15,"type":10,"description":16,"interventionNames":17},"D-2570 High Dose","medium dose level of D-2570",[13],{"label":19,"type":20,"description":21,"interventionNames":22},"Placebo","PLACEBO_COMPARATOR","Placebo arm",[23],"Drug: Placebo Tablets",[25,31],{"type":26,"name":27,"description":28,"armGroupLabels":29,"otherNames":30},"DRUG","D-2570 Tablet","Active Treatment",[15,9],null,{"type":26,"name":32,"description":33,"armGroupLabels":34,"otherNames":30},"Placebo Tablets","Identical Tablet",[19],[36],{"name":37,"role":38,"phone":39,"phoneExt":30,"email":40},"Kathryn Stazzone","CONTACT","3025195966","kathryn.stazzone@inventisbio.com",[42,59],{"facility":43,"status":44,"city":45,"state":46,"zip":47,"country":48,"countryCode":49,"cosmosGeoPoint":50,"geoPoint":55,"contacts":56},"Study Center","RECRUITING","Birmingham","Alabama","35244","United States","US",{"type":51,"coordinates":52},"Point",[53,54],-86.80249,33.52066,{"lat":54,"lon":53},[57],{"name":37,"role":38,"phone":58,"phoneExt":30,"email":40},"302-519-5966",{"facility":43,"status":44,"city":60,"state":61,"zip":62,"country":48,"countryCode":49,"cosmosGeoPoint":63,"geoPoint":67,"contacts":68},"Chula Vista","California","91910",{"type":51,"coordinates":64},[65,66],-117.0842,32.64005,{"lat":66,"lon":65},[69],{"name":37,"role":38,"phone":58,"phoneExt":30,"email":40},{"type":71,"investigatorFullName":30,"investigatorTitle":30,"investigatorAffiliation":30,"oldNameTitle":30,"oldOrganization":30},"SPONSOR","100630608","phase-2-a-study-to-evaluate-d-2570-in-participants-with-moderate-to-severe-plaque-psoriasis-100630608",false,"NCT07489885","A Study to Evaluate D-2570 in Participants With Moderate to Severe Plaque Psoriasis","A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Study to Evaluate the Efficacy and Safety of D-2570 in Participants With Moderate to Severe Plaque Psoriasis","N\u002FZ","Inclusion Criteria:\n\n* Participants with a diagnosis of plaque psoriasis with no significant flares of disease activity for at least 6 months before signing the informed consent\n* Participants have moderate to severe plaque psoriasis as defined by a total body surface area (BSA) ≥10%, a Psoriasis Area and Severity Index (PASI) score ≥ 12 and a Physician's Global Assessment (PGA) score ≥ 3.\n* Within normal ranges of laboratory assessments\n\nExclusion Criteria:\n\n* Any comorbidities or past medical conditions as outlined in the protocol that would interfere with study assessments as deemed by the Investigator","ALL","18 Years","70 Years",{"count":84,"type":85},75,"ESTIMATED","INTERVENTIONAL",[88],"PHASE2","A Study looking at the safety and efficacy of D-2570 in Participants with Plaque Psoriasis",[91],"Psoriasis",[93],"Moderate to Severe Plaque Psoriasis","2026-06-17",{"date":96,"type":97},"2026-06-22","ACTUAL",{"date":99,"type":97},"2026-06-03",{"date":101,"type":85},"2027-12",{"name":5,"class":6},2]